Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system

Our comprehensive pharmacovigilance analysis identified distinct adverse event profiles and significant drug-specific safety signals among TKIs used in GIST treatment. These findings enhance the characterization of TKI safety, revealing previously unreported or strongly associated signals and highlighting differences between agents. This evidence contributes to a better understanding of TKI-associated risks in clinical practice.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2025-08-29
DOI
https://doi.org/10.3389/fonc.2025.1608451
Citations
1
Primary Topic
Gastrointestinal Tumor Research and Treatment
Type
article
Field-Weighted Citation Impact
1.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system

Shenhui Xu, Ahui Fan, Xin Liu, Yuhao Wang et al.
1 citations
Frontiers in Oncology
Gastrointestinal Tumor Research and Treatment
1.81
article

Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system

Shenhui Xu, Ahui Fan, Xin Liu, Yuhao Wang, Yi Ma, Jianjun Yang
article en
1 citations

Abstract

Our comprehensive pharmacovigilance analysis identified distinct adverse event profiles and significant drug-specific safety signals among TKIs used in GIST treatment. These findings enhance the characterization of TKI safety, revealing previously unreported or strongly associated signals and highlighting differences between agents. This evidence contributes to a better understanding of TKI-associated risks in clinical practice.

Frontiers in OncologyVol. 15
National Clinical Research Center for Digestive Diseases (CN), Xijing Hospital (CN), Air Force Medical University (CN)
National Natural Science Foundation of China, Fourth Military Medical University
Openalex Percentile: Top 13%
Gastrointestinal Tumor Research and Treatment
1.81
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system — Shenhui Xu, Ahui Fan, et al. · Frontiers in Oncology (2025) | TGRS Research Map | TGRS